{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:30:48Z","timestamp":1793640648421,"version":"4.5.1"},"reference-count":56,"publisher":null,"issue":"7","license":[{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>This article summarizes current information about the interrelation between testosterone concentrations and chronic heart failure (CHF). The authors described key publications that address the prevalence of testosterone deficiency in patients with CHF, the effect of endogenous and exogenous testosterone on the cardiovascular system, the relationship between testosterone levels and the severity and prognosis of CHF, and the efficacy of interventional treatments for CHF.<\/jats:p>","DOI":"10.18087\/cardio.2022.7.n1242","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T09:53:02Z","timestamp":1661161982000},"page":"61-67","source":"Crossref","is-referenced-by-count":1,"title":["Testosterone and congestive heart failure"],"prefix":"10.68900","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-2952","authenticated-orcid":true,"given":"T. N.","family":"Enina","sequence":"first","affiliation":[{"name":"Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Tomsk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-9131","authenticated-orcid":true,"given":"V. A.","family":"Kuznetsov","sequence":"additional","affiliation":[{"name":"Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Tomsk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Soldatova","sequence":"additional","affiliation":[{"name":"Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Tomsk"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2022,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Cruz-Topete D, Dominic P, Stokes KY. Uncovering sex-specific mechanisms of action of testosterone and redox balance. Redox Biology. 2020;31:101490. DOI: 10.1016\/j.redox.2020.101490","DOI":"10.1016\/j.redox.2020.101490"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, Laurindo FR et al. Testosterone Induces Vascular Smooth Muscle Cell Migration by NADPH Oxidase and c-Src\u2013Dependent Pathways. Hypertension. 2012;59(6):1263\u201371. DOI: 10.1161\/HYPERTENSIONAHA.111.180620","DOI":"10.1161\/HYPERTENSIONAHA.111.180620"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Pingili AK, Kara M, Khan NS, Estes AM, Lin Z, Li W et al. 6\u03b2-Hydroxytestosterone, a Cytochrome P450 1B1 Metabolite of Testosterone, Contributes to Angiotensin II\u2013Induced Hypertension and Its Pathogenesis in Male Mice. Hypertension. 2015;65(6):1279\u201387. DOI: 10.1161\/HYPERTENSIONAHA.115.05396","DOI":"10.1161\/HYPERTENSIONAHA.115.05396"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Zhang L, Wu S, Hong L, Xing X, Lai W. Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. Molecular Medicine Reports. 2011;11:1183\u20131188. DOI: 10.3892\/mmr.2011.539","DOI":"10.3892\/mmr.2011.539"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Xiao F-Y, Nheu L, Komesaroff P, Ling S. Testosterone protects cardiac myocytes from superoxide injury via NF-\u03baB signalling pathways. Life Sciences. 2015;133:45\u201352. DOI: 10.1016\/j.lfs.2015.05.009","DOI":"10.1016\/j.lfs.2015.05.009"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Frontiers in Neuroendocrinology. 2008;29(2):169\u201381. DOI: 10.1016\/j.yfrne.2007.10.005","DOI":"10.1016\/j.yfrne.2007.10.005"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Lorigo M, Mariana M, Lemos MC, Cairrao E. Vascular mechanisms of testosterone: The non-genomic point of view. The Journal of Steroid Biochemistry and Molecular Biology. 2020;196:105496. DOI: 10.1016\/j.jsbmb.2019.105496","DOI":"10.1016\/j.jsbmb.2019.105496"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Thirumalai A, Rubinow KB, Page ST. An update on testosterone, HDL and cardiovascular risk in men. Clinical Lipidology. 2015;10(3):251\u2013 8. DOI: 10.2217\/clp.15.10","DOI":"10.2217\/clp.15.10"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Coward R, Carson C, McBride J. Diagnosis and management of testosterone deficiency. Asian Journal of Andrology. 2015;17(2):177\u201386. DOI: 10.4103\/1008-682X.143317","DOI":"10.4103\/1008-682X.143317"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. Baltimore Longitudinal Study of Aging. The Journal of Clinical Endocrinology and Metabolism. 2001;86(2):724\u201331. DOI: 10.1210\/jcem.86.2.7219","DOI":"10.1210\/jcem.86.2.7219"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Melnichenko G.A., Shestakova M.V., Rozhivanov R.V., Terehova A.L., Zilov A.V., Ladygina D.O. et al. Guidelines for the diagnosis and treatment of testosterone deficiency (hypogonadism) in male patients with diabetes mellitus. Diabetes mellitus. 2017;20(2):151\u201360. DOI: 10.14341\/7884","DOI":"10.14341\/7884"},{"key":"ref12","unstructured":"Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A et al. EAU Guidelines on Sexus and Reproductive Health. Av. at: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2020.pdf. 2020."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715\u201344. DOI: 10.1210\/jc.2018-00229","DOI":"10.1210\/jc.2018-00229"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex Steroids and All-Cause and Cause-Specific Mortality in Men. Archives of Internal Medicine. 2007;167(12):1252\u201360. DOI: 10.1001\/archinte.167.12.1252","DOI":"10.1001\/archinte.167.12.1252"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kirby M, Hackett G, Ramachandran S. Testosterone and the Heart. European Cardiology Review. 2019;14(2):103\u201310. DOI: 10.15420\/ecr.2019.13.1","DOI":"10.15420\/ecr.2019.13.1"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Jankowska EA, Tkaczyszyn M, Kalici\u0144ska E, Banasiak W, Ponikowski P. Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. Kardiologia Polska. 2014;72(5):403\u20139. DOI: 10.5603\/KP.a2014.0025","DOI":"10.5603\/KP.a2014.0025"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694\u2013701. DOI: 10.1161\/CIRCULATIONAHA.107.719005","DOI":"10.1161\/CIRCULATIONAHA.107.719005"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2011;96(10):3007\u201319. DOI: 10.1210\/jc.2011-1137","DOI":"10.1210\/jc.2011-1137"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology. 2011;165(5):687\u2013701. DOI: 10.1530\/EJE-11-0447","DOI":"10.1530\/EJE-11-0447"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Laughlin GA, Barrett-Connor E, Bergstrom J. Low Serum Testosterone and Mortality in Older Men. The Journal of Clinical Endocrinology & Metabolism. 2008;93(1):68\u201375. DOI: 10.1210\/jc.2007-1792","DOI":"10.1210\/jc.2007-1792"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK et al. High Serum Testosterone Is Associated With Reduced Risk of Cardiovascular Events in Elderly Men. Journal of the American College of Cardiology. 2011;58(16):1674\u201381. DOI: 10.1016\/j.jacc.2011.07.019","DOI":"10.1016\/j.jacc.2011.07.019"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Chan YX, Knuiman MW, Hung J, Divitini ML, Beilby JP, Handelsman DJ et al. Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and non-fatal cardiovascular events, and mortality in men aged 17-97 years. Clinical Endocrinology. 2016;85(4):575\u201382. DOI: 10.1111\/cen.13089","DOI":"10.1111\/cen.13089"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Collet T-H, Ewing SK, Ensrud KE, Laughlin GA, Hoffman AR, Varosy PD et al. Endogenous Testosterone Levels and the Risk of Incident Cardiovascular Events in Elderly Men: The MrOS Prospective Study. Journal of the Endocrine Society. 2020;4(5):bvaa038. DOI: 10.1210\/jendso\/bvaa038","DOI":"10.1210\/jendso\/bvaa038"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yeap BB, Alfonso H, Chubb SAP, Handelsman DJ, Hankey GJ, Almeida OP et al. In Older Men an Optimal Plasma Testosterone Is Associated With Reduced All-Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality. The Journal of Clinical Endocrinology & Metabolism. 2014;99(1):E9\u201318. DOI: 10.1210\/jc.2013-3272","DOI":"10.1210\/jc.2013-3272"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Yeap B. Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular events in men. Asian Journal of Andrology. 2018;20(2):109\u201314. DOI: 10.4103\/aja.aja_50_17","DOI":"10.4103\/aja.aja_50_17"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wang W, Jiang T, Li C, Chen J, Cao K, Qi L-W et al. Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. Journal of Thoracic Disease. 2016;8(5):E269\u201377. DOI: 10.21037\/jtd.2016.03.39","DOI":"10.21037\/jtd.2016.03.39"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Yoshihisa A, Suzuki S, Sato Y, Kanno Y, Abe S, Miyata M et al. Relation of Testosterone Levels to Mortality in Men With Heart Failure. The American Journal of Cardiology. 2018;121(11):1321\u20137. DOI: 10.1016\/j.amjcard.2018.01.052","DOI":"10.1016\/j.amjcard.2018.01.052"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Mehra MR. Fat, Cachexia, and the Right Ventricle in Heart Failure. Journal of the American College of Cardiology. 2013;62(18):1671\u20133. DOI: 10.1016\/j.jacc.2013.07.021","DOI":"10.1016\/j.jacc.2013.07.021"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Nguyen AB, Imamura T, Besser S, Rodgers D, Chung B, Raikhelkar J et al. Metabolic Dysfunction in Continuous\u2010Flow Left Ventricular Assist Devices Patients and Outcomes. Journal of the American Heart Association. 2019;8(22):e013278. DOI: 10.1161\/JAHA.119.013278","DOI":"10.1161\/JAHA.119.013278"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Naderi N, Heidarali M, Barzegari F, Ghadrdoost B, Amin A, Taghavi S. Hormonal Profile in Patients With Dilated Cardiomyopathy. Research in Cardiovascular Medicine. 2015;4(3):e27631. DOI: 10.5812\/ cardiovascmed.27631v2","DOI":"10.5812\/cardiovascmed.27631v2"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M et al. Testosterone Therapy in Women With Chronic Heart Failure. Journal of the American College of Cardiology. 2010;56(16):1310\u20136. DOI: 10.1016\/j.jacc.2010.03.090","DOI":"10.1016\/j.jacc.2010.03.090"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC medicine. 2013;11:108. DOI: 10.1186\/1741-7015-11-108","DOI":"10.1186\/1741-7015-11-108"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"K\u00f6nig CS, Balabani S, Hackett GI, Strange RC, Ramachandran S. Testosterone Therapy: An Assessment of the Clinical Consequences of Changes in Hematocrit and Blood Flow Characteristics. Sexual Medicine Reviews. 2019;7(4):650\u201360. DOI: 10.1016\/j.sxmr.2019.01.003","DOI":"10.1016\/j.sxmr.2019.01.003"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy on QT dispersion in men with heart failure. The American Journal of Cardiology. 2003;92(10):1241\u20133. DOI: 10.1016\/j.amjcard.2003.07.044","DOI":"10.1016\/j.amjcard.2003.07.044"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Schwartz JB, Volterrani M, Caminiti G, Marazzi G, Fini M, Rosano GMC et al. Effects of testosterone on the Q-T Interval in older men and older women with chronic heart failure. International Journal of Andrology. 2011;34(5 Pt 2):e415\u201321. DOI: 10.1111\/j.1365-2605.2011.01163.x","DOI":"10.1111\/j.1365-2605.2011.01163.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Zeller T, Schnabel RB, Appelbaum S, Ojeda F, Berisha F, Schulte-Steinberg B et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women \u2013 results from the FINRISK study. European Journal of Preventive Cardiology. 2018;25(11):1133\u20139. DOI: 10.1177\/2047487318778346","DOI":"10.1177\/2047487318778346"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Berger D, Folsom AR, Schreiner PJ, Chen LY, Michos ED, O\u2019Neal WT et al. Plasma total testosterone and risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Maturitas. 2019;125:5\u201310. DOI: 10.1016\/j.maturitas.2019.03.015","DOI":"10.1016\/j.maturitas.2019.03.015"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Enina T.N., Kuznetsov V.A., Soldatova A.M., Petelina T.I., Krinochkin D.V., Dyachkov S.M. et al. Relationship between levels of sex hormones and response to cardiac resynchronisation therapy in men. Kardiologiia. 2018;58(S7):24\u201335. DOI: 10.18087\/cardio.2464","DOI":"10.18087\/cardio.2464"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Lucia C de, Eguchi A, Koch WJ. New Insights in Cardiac \u03b2-Adrenergic Signaling During Heart Failure and Aging. Frontiers in Pharmacology. 2018;9:904. DOI: 10.3389\/fphar.2018.00904","DOI":"10.3389\/fphar.2018.00904"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Nguyen M-N, Kiriazis H, Ruggiero D, Gao X-M, Su Y, Jian A et al. Spontaneous ventricular tachyarrhythmias in \u03b22-adrenoceptor transgenic mice in relation to cardiac interstitial fibrosis. American Journal of Physiology-Heart and Circulatory Physiology. 2015;309(5):H946\u2013 57. DOI: 10.1152\/ajpheart.00405.2015","DOI":"10.1152\/ajpheart.00405.2015"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Sun J, Fu L, Tang X, Han Y, Ma D, Cao J et al. Testosterone modulation of cardiac \u03b2-adrenergic signals in a rat model of heart failure. General and Comparative Endocrinology. 2011;172(3):518\u201325. DOI: 10.1016\/j.ygcen.2011.04.019","DOI":"10.1016\/j.ygcen.2011.04.019"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS et al. Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure. New England Journal of Medicine. 1984;311(13):819\u201323. DOI: 10.1056\/NEJM198409273111303","DOI":"10.1056\/NEJM198409273111303"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Han Y, Fu L, Sun W, Cao J, Xie R, Zhou P et al. Neuroprotective effects of testosterone upon cardiac sympathetic function in rats with induced heart failure. European Journal of Pharmacology. 2009;619(1\u20133):68\u201374. DOI: 10.1016\/j.ejphar.2009.07.023","DOI":"10.1016\/j.ejphar.2009.07.023"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Vergaro G, Aimo A, Prontera C, Ghionzoli N, Arzilli C, Zyw L et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology. 2019;296:91\u20137. DOI: 10.1016\/j.ijcard.2019.08.040","DOI":"10.1016\/j.ijcard.2019.08.040"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA et al. Testosterone Supplementation in Heart Failure: A Meta-Analysis. Circulation: Heart Failure. 2012;5(3):315\u201321. DOI: 10.1161\/CIRCHEARTFAILURE.111.965632","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Tao J, Liu X, Bai W. Testosterone Supplementation in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology. 2020;11:110. DOI: 10.3389\/fendo.2020.00110","DOI":"10.3389\/fendo.2020.00110"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Schmid FA, Schlager O, Keller P, Seifert B, Huang R, Fr\u00f6hlich GM et al. Prognostic value of long-term blood pressure changes in patients with chronic heart failure. European Journal of Heart Failure. 2017;19(7):837\u201342. DOI: 10.1002\/ejhf.805","DOI":"10.1002\/ejhf.805"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Pugh P, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. European Heart Journal. 2003;24(10):909\u201315. DOI: 10.1016\/S0195-668X(03)00083-6","DOI":"10.1016\/S0195-668X(03)00083-6"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Arcopinto M, Salzano A, Bossone E, Ferrara F, Bobbio E, Sirico D et al. Multiple hormone deficiencies in chronic heart failure. International Journal of Cardiology. 2015;184:421\u20133. DOI: 10.1016\/j.ijcard.2015.02.055","DOI":"10.1016\/j.ijcard.2015.02.055"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Salzano A, Marra AM, Arcopinto M, D\u2019Assante R, Triggiani V, Coscioni E et al. Combined effects of growth hormone and testosterone replacement treatment in heart failure. ESC Heart Failure. 2019;6(6):1216\u201321. DOI: 10.1002\/ehf2.12520","DOI":"10.1002\/ehf2.12520"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM et al. Adverse Events Associated with Testosterone Administration. New England Journal of Medicine. 2010;363(2):109\u201322. DOI: 10.1056\/NEJMoa1000485","DOI":"10.1056\/NEJMoa1000485"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Vigen R, O\u2019Donnell CI, Bar\u00f3n AE, Grunwald GK, Maddox TM, Bradley SM et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013;310(17):1829. DOI: 10.1001\/jama.2013.280386","DOI":"10.1001\/jama.2013.280386"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE. 2014;9(1):e85805. DOI: 10.1371\/journal.pone.0085805","DOI":"10.1371\/journal.pone.0085805"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Elagizi A, K\u00f6hler TS, Lavie CJ. Testosterone and Cardiovascular Health. Mayo Clinic Proceedings. 2018;93(1):83\u2013100. DOI: 10.1016\/j.mayocp.2017.11.006","DOI":"10.1016\/j.mayocp.2017.11.006"},{"key":"ref55","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA. 2019; [Av. at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drugsafety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due]"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Simsek E, Kilic S, Kemal HS, Nalbantgil S, Ozturk P, Yildirim I et al. Effect of Testosterone Level on Mortality in Patients With Left Ventricular Assist Device. Transplantation Proceedings. 2019;51(10):3418\u201323. DOI: 10.1016\/j.transproceed.2019.07.028","DOI":"10.1016\/j.transproceed.2019.07.028"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1242\/1254","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:20Z","timestamp":1793639780000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,31]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,31]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2022.7.n1242","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,31]]}}}